No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Operating as a pharmaceutical firm, Alkem Laboratories Limited is actively engaged in the research, manufacturing, and commercialization of medicinal and nutritional products, distributed both within India and internationally. The company's diverse product range includes branded and unbranded generic medications, active pharmaceutical ingredients (APIs), biosimilars, and various nutraceuticals. These solutions cater to numerous acute and chronic health concerns, spanning anti-infective therapies, dermatology, cardiology, respiratory ailments, gastrointestinal health, central nervous system disorders, urology, and gynaecology. Additionally, their offerings encompass vital vitamins, minerals, and nutrients, as well as products for pain relief, diabetes management, and neurological conditions. Alkem Laboratories Limited was founded in 1973 and has its main operational base in Mumbai, India.
www.alkemlabs.comNo one on the platform currently holds ALKEM.BO.
No tracked institution reports a position in ALKEM.BO as of their last filing.
No one on the platform has traded ALKEM.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.7% | 13.7% | 14.1% | — | — | — |
| Rev. Growth % | 14.9% | 11.0% | ||||
| Profit Margin % | 15.6% | 14.3% | 14.0% | |||
| Free Cash Flow Margin % | 9.1% | 10.5% | 6.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $166.9B | +14.2% | $193.69 | $182.75–$218.08 | — | 18 |
| 2028 | $185.6B | +11.2% | $225.50 | $203.38–$257.81 | — | 17 |
| 2029 | $205.2B | +10.5% | $257.44 | $229.18–$278.56 | — | 10 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $47.04 | $43.50 | -7.5% |
| 2026-05-28 | $36.19 | $19.80 | -45.3% |
| 2026-02-12 | $57.79 | $53.19 | -8.0% |
| 2025-11-13 | $58.65 | $63.99 | +9.1% |
| 2025-08-11 | $45.10 | $55.60 | +23.3% |
| 2025-05-28 | $29.28 | $25.60 | -12.6% |
| 2025-02-06 | $51.24 | $52.34 | +2.1% |
| 2024-11-13 | $57.78 | $57.60 | -0.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ALKEM.BOAlkem Laboratories Limited | $5089.50 | -0.41% | $607.6B | — |
| ABBOTINDIA.BOAbbott India Limited | $25570.00 | +1.18% | $543.9B | — |
| ABBOTINDIA.NSAbbott India Limited | $25550.00 | +1.15% | $542.9B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1675.45 | +0.39% | $963.7B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1679.80 |
| +0.68% |
| $966.5B |
| — |
| GLENMARK.BOGlenmark Pharmaceuticals Limited | $2416.90 | -0.00% | $698.1B | — |
| GLENMARK.NSGlenmark Pharmaceuticals Limited | $2419.20 | +0.17% | $682.7B | — |
Source: Financial Modeling Prep · peers by sector/industry